Further to your request for information dated the 3 February 2016 and the further information received on 17 February 2016, the information requested is below:

1. **How many people with MS in your CCG (including the source for this number):**
   a. Relapsing-Remitting MS
   b. Primary Progressive MS
   c. Secondary Progressive MS
   d. Benign MS
   e. Unconfirmed Type

NHS Dartford Gravesham and Swanley Clinical Commissioning Group (CCG) does not hold this information. Please refer to the Public Health Team at Kent County Council.

Public Health
Kent County Council
Maidstone
Kent ME14 1XQ

Email  freedomofinformation@kent.gov.uk

2. **The percentage of each of 1a, 1b, 1c, 1d, and 1e, who receive an annual review by a healthcare professional with expertise in MS, and its complications (NICE guidelines (CG 186)).**

The CCG does not hold this information. Please refer to the provider of this service, Dartford and Gravesham NHS Trust. The CCG understands that this clinical guideline is currently under review by secondary care providers.

FOI Act Lead
4th Floor, Information Department
Dartford & Gravesham NHS Trust
Darent Valley Hospital
Darenth Wood Road
Dartford
Kent DA2 8DA

https://www.dvh.nhs.uk/about-us/freedomof-information/form/
3. The current waiting times targets for accessing an appointment with a Consultant Neurologist with MS expertise for:

   a. New appointments
   
   b. Follow up appointments

All referrals are subject to the 18 week Referral to Treatment (RTT) standard. There are no specific timescales for new and follow-up appointments but all patients have a right under the NHS Constitution to receive definitive treatment within 18 weeks of referral by their GP.

4. The number of Individual Funding Requests (IFRs) received for each of the below treatments

<table>
<thead>
<tr>
<th>Treatment</th>
<th>DGS</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Avonex (Beta interferon – 1a)</td>
<td>0</td>
</tr>
<tr>
<td>b. Aubagio® (Teriflunomide)</td>
<td>0</td>
</tr>
<tr>
<td>c. Betaferon (Interferon beta 1b)</td>
<td>0</td>
</tr>
<tr>
<td>d. Botox (Botulinum toxin)</td>
<td>5</td>
</tr>
<tr>
<td>e. Copaxone (Glatiramer Acetate)</td>
<td>0</td>
</tr>
<tr>
<td>f. Extavia (Beta interferon – 1b)</td>
<td>0</td>
</tr>
<tr>
<td>g. Fampyra® (Fampridine)</td>
<td>0</td>
</tr>
<tr>
<td>h. Gilenya (Fingolimod)</td>
<td>0</td>
</tr>
<tr>
<td>i. Lemtrada (Alemtuzumab)</td>
<td>0</td>
</tr>
<tr>
<td>j. Plegridy (Peginterferon beta 1a)</td>
<td>0</td>
</tr>
<tr>
<td>k. Rebif® (Beta interferon – 1a)</td>
<td>0</td>
</tr>
<tr>
<td>l. Sativex (Nabiximols)</td>
<td>0</td>
</tr>
<tr>
<td>m. Tecfidera (Dimethyl fumarate)</td>
<td>0</td>
</tr>
<tr>
<td>n. Tysabri (Natalizumab)</td>
<td>0</td>
</tr>
</tbody>
</table>
5. The number of people with MS currently being prescribed the following licensed treatments for multiple sclerosis

   a. Avonex (Beta interferon – 1a)
   b. Aubagio® (Teriflunomide)
   c. Betaferon (Interferon beta 1b)
   d. Botox (Botulinum toxin)
   e. Copaxone (Glatiramer Acetate)
   f. Extavia (Beta interferon – 1b)
   g. Fampyra® (Fampridine)
   h. Gilenya (Fingolimod)
   i. Lemtrada (Alemtuzumab)
   j. Plegridy (Peginterferon beta 1a)
   k. Rebif® (Beta interferon – 1a)
   l. Sativex (Nabiximols)
   m. Tecfidera (Dimethyl fumarate)
   n. Tysabri (Natalizumab)

The CCG does not hold patient data so are unable to respond to this query. Additionally some of the drugs are high cost and South East Commissioning Support Unit may have this information. Please refer to

South East Commissioning Support Unit
Kent House
81 Station Road
Ashford
Kent
TN23 1PP

Email : foi@nhs.net